Pleural Mesothelioma Survival Rate: What to Know

Quick answer: Pleural Mesothelioma Survival Rate: the American Cancer Society reports a 5-year relative survival rate of about 12% for all pleural mesothelioma stages combined, based on SEER data.

Survival varies by stage, age, health, cell type, and treatment; patients should ask an oncology specialist for prognosis, not rely on averages alone.

Pleural Mesothelioma Survival Rate is commonly reported as a median survival of about 12 to 21 months after diagnosis, depending on stage, cell type and treatment, according to summaries from the American Cancer Society and National Cancer Institute.

Population data from the National Cancer Institute’s SEER program show 5-year relative survival varies sharply by spread at diagnosis: localized, regional or distant. These figures are estimates, not personal predictions.

Patients should not make treatment or legal decisions from survival statistics alone; an oncologist should interpret individual prognosis.

Infographic shows pleural mesothelioma survival percentages with lung images and icons — everyday paperwork behind pleural mesothelioma survival rate.

Pleural mesothelioma survival rate overview

Pleural mesothelioma survival rates are usually reported as relative survival, median overall survival, or trial-based overall survival. These figures describe groups of patients, not what will happen to one person.

The most cited U.S. survival benchmark comes from the American Cancer Society, using National Cancer Institute SEER data for people diagnosed with pleural mesothelioma between 2012 and 2018.

SEER stage at diagnosis	Meaning	5-year relative survival rate	Source
Localized	Cancer appears limited to the pleura	24%	American Cancer Society, SEER 2012-2018
Regional	Cancer has spread to nearby structures or lymph nodes	16%	American Cancer Society, SEER 2012-2018
Distant	Cancer has spread to distant parts of the body	7%	American Cancer Society, SEER 2012-2018
All SEER stages combined	All pleural mesothelioma cases in the dataset	12%	American Cancer Society, SEER 2012-2018

These numbers show why stage matters. Earlier-stage pleural mesothelioma has better recorded survival, but even localized disease remains aggressive compared with many other cancers.

The National Cancer Institute’s PDQ summary states that malignant mesothelioma has a median survival of about 1 year after diagnosis, although outcomes vary by stage, cell type, age, performance status, and treatment.

Treatment setting	Survival figure	Source
Previously untreated, unresectable malignant pleural mesothelioma treated with nivolumab plus ipilimumab	Median overall survival: 18.1 months	CheckMate 743 trial, published in The Lancet
Previously untreated, unresectable malignant pleural mesothelioma treated with platinum-based chemotherapy plus pemetrexed	Median overall survival: 14.1 months	CheckMate 743 trial, published in The Lancet

Histology is also important. The National Cancer Institute identifies epithelial mesothelioma as having a better prognosis than sarcomatoid or biphasic disease, but individual estimates require pathology review and staging.

Better outlook is generally linked to: Earlier stage, epithelial cell type, good functional status, younger age, and access to specialist care.
Worse outlook is generally linked to: Distant spread, sarcomatoid histology, poor performance status, weight loss, and major coexisting illness.
Caution: Do not use survival tables alone to choose treatment, delay care, or estimate legal or financial needs. A mesothelioma oncologist should interpret prognosis using current scans, pathology, and treatment options.

Hospital hallway counter displays lung brochures and a framed lung illustration.

Survival rates by disease stage

Pleural mesothelioma survival generally falls as cancer spreads beyond the lining of the lung.

The most widely cited U.S. stage-based figures come from the American Cancer Society, using National Cancer Institute SEER data for diagnoses from 2013 to 2019.

These figures are 5-year relative survival rates, meaning they compare people with pleural mesothelioma with people in the general population of the same age and sex. They are not a personal prediction.

SEER stage at diagnosis	What it generally means	5-year relative survival rate	Source
Localized	Cancer appears limited to the pleura, the lining around the lung.	24%	American Cancer Society, based on SEER 2013-2019 data
Regional	Cancer has spread to nearby tissues, organs or regional lymph nodes.	16%	American Cancer Society, based on SEER 2013-2019 data
Distant	Cancer has spread to distant organs or distant lymph nodes.	7%	American Cancer Society, based on SEER 2013-2019 data
All SEER stages combined	Includes localized, regional, distant and unstaged pleural mesothelioma.	12%	American Cancer Society, based on SEER 2013-2019 data

SEER stages are broader than the AJCC TNM staging system used by many oncologists. A doctor may describe pleural mesothelioma as stage 1, 2, 3 or 4, based on tumor location, lymph node involvement and distant spread.

In general, earlier-stage pleural mesothelioma has better survival because surgery, chemotherapy, immunotherapy or radiation may be more feasible.

Later-stage disease is harder to control because it more often involves the chest wall, diaphragm, lymph nodes or distant sites.

Localized disease: Survival is highest in SEER data, but only some patients are medically fit for aggressive treatment.
Regional disease: Survival is lower, often because nearby structures or lymph nodes are involved.
Distant disease: Survival is lowest in SEER data, reflecting spread beyond the original chest area.

Caution: Do not use these percentages to decide whether to accept, refuse or delay treatment. Mesothelioma survival depends on cell type, age, overall health, treatment response, surgical eligibility and specialist care.

Patients should ask their oncology team which staging system is being used and whether their case is comparable to SEER “localized,” “regional” or “distant” categories.

Clinical trials may also change expectations for some patients.

Wooden table holds a chart printout, pill organizer, and eyeglasses near a window — the kind of desk where pleural mesothelioma survival rate gets worked out.

How treatment affects survival time

Treatment can change pleural mesothelioma survival time, but the effect depends strongly on stage, cell type, performance status, age, and whether the cancer can be safely treated with multiple therapies.

Median survival figures describe groups, not an individual prognosis.

Caution: No patient should choose chemotherapy, immunotherapy, radiation, or surgery from survival statistics alone.

Pleural mesothelioma treatment decisions should be reviewed with a mesothelioma-experienced oncology team and, when relevant, a thoracic surgeon.

Treatment setting	Study/source	Key survival result
Cisplatin plus pemetrexed chemotherapy	Vogelzang et al., Journal of Clinical Oncology, 2003	Median overall survival was 12.1 months, compared with 9.3 months for cisplatin alone.
Nivolumab plus ipilimumab for unresectable disease	CheckMate 743, The Lancet, 2021	Median overall survival was 18.1 months, compared with 14.1 months for platinum-pemetrexed chemotherapy.
Chemotherapy plus bevacizumab	MAPS trial, The Lancet, 2016	Median overall survival was 18.8 months, compared with 16.1 months for chemotherapy without bevacizumab.
Tumor Treating Fields with chemotherapy	STELLAR phase 2 study, The Lancet Oncology, 2019	Median overall survival was 18.2 months; this was a single-arm study, not a randomized comparison.

Systemic therapy is the main treatment for many patients because pleural mesothelioma is often diagnosed after it has spread across the pleura.

The 2003 pemetrexed-cisplatin trial established a survival advantage over cisplatin alone and became a long-standing chemotherapy standard.

Immunotherapy changed first-line treatment for unresectable pleural mesothelioma.

In CheckMate 743, the survival benefit was especially notable in non-epithelioid disease, where median overall survival was 18.1 months with nivolumab-ipilimumab versus 8.8 months with chemotherapy, according to the published trial.

Surgery is more complicated. Operations such as pleurectomy/decortication or extrapleural pneumonectomy may be considered only for carefully selected patients, usually with multimodality treatment.

Selection itself affects survival statistics, because surgical candidates are often healthier and have earlier-stage disease.

The MARS 2 randomized trial, reported in The Lancet Respiratory Medicine, found that adding extended pleurectomy/decortication to chemotherapy did not improve survival in the studied group.

Reported median overall survival was 19.3 months with surgery plus chemotherapy and 24.8 months with chemotherapy alone.

Earlier stage disease generally leaves more treatment options available.
Epithelioid histology usually has better survival than sarcomatoid or biphasic disease.
Clinical trials may offer access to newer combinations, but risks and eligibility criteria vary.

Bottom line: Treatment can extend survival for some patients, but the best option is highly individualized. Patients should ask their care team which published evidence applies to their exact stage, histology, health status, and treatment goals.

Exam room wall displays a lung anatomy poster and blank calendar board. A common setting for pleural mesothelioma survival rate.

Factors that influence individual prognosis

Pleural mesothelioma survival varies widely because prognosis depends on tumor biology, stage, overall health and treatment options. Population averages are useful for context, but they cannot predict how long any one person will live.

Caution: Do not use survival statistics alone to make treatment, legal or financial decisions. A mesothelioma specialist, oncologist and qualified attorney can interpret medical records and state-specific deadlines.

Stage at diagnosis: Earlier-stage pleural mesothelioma is usually associated with longer survival because disease may be more limited and more treatment options may be available.
Cell type: Epithelioid tumors generally have a better prognosis than biphasic or sarcomatoid tumors. The National Cancer Institute identifies histologic subtype as an important prognostic factor in malignant mesothelioma.
Performance status: Patients who can carry out daily activities and tolerate treatment often do better than patients with major frailty or severe symptoms.
Age and other illnesses: Heart disease, lung disease, kidney problems and poor nutrition can limit chemotherapy, immunotherapy, surgery or radiation options.
Treatment access: Outcomes may differ when patients are evaluated at high-volume centers with experience in mesothelioma surgery, systemic therapy and clinical trials.

SEER stage for pleural mesothelioma	5-year relative survival	Source
Localized	24%	American Cancer Society, based on SEER data for people diagnosed 2012-2018
Regional	16%	American Cancer Society, based on SEER data for people diagnosed 2012-2018
Distant	7%	American Cancer Society, based on SEER data for people diagnosed 2012-2018
All SEER stages combined	12%	American Cancer Society, based on SEER data for people diagnosed 2012-2018

Stage statistics can be misleading for an individual patient. The American Cancer Society notes that SEER categories do not capture every clinical detail, such as whether surgery is possible or how well a patient responds to therapy.

Treatment evidence	Survival finding	Source
Nivolumab plus ipilimumab vs platinum-pemetrexed chemotherapy	Median overall survival was 18.1 months vs 14.1 months	CheckMate 743 trial, published in The Lancet in 2021
Cisplatin plus pemetrexed vs cisplatin alone	Median survival was 12.1 months vs 9.3 months	Vogelzang et al., Journal of Clinical Oncology, 2003

These trial results describe groups of eligible patients, not guaranteed outcomes. Some people live much longer than the median, while others decline quickly because of aggressive disease, complications or inability to tolerate treatment.

Prognosis is best discussed after pathology review, imaging, staging and assessment by a multidisciplinary team. Patients should ask whether clinical trials, palliative care and symptom control are appropriate alongside disease-directed treatment.

Wooden desk holds papers, folders, envelope, pen, lamp, and paper clips.

Interpreting median survival and life expectancy

For pleural mesothelioma, “median survival” is often more useful than a broad life-expectancy estimate. It means half of patients in a study lived longer than that time and half lived less, not that any one person has a fixed deadline.

Published survival figures depend heavily on stage, cell type, age, performance status, and treatment eligibility.

A patient should not use population averages to delay care, choose treatment, or make legal or financial decisions without advice from an oncology team and qualified professionals.

Measure	What it means	Specific published figure	Source
Median overall survival with first-line immunotherapy	Middle survival time in a clinical trial population	18.1 months with nivolumab plus ipilimumab, compared with 14.1 months with platinum-pemetrexed chemotherapy	CheckMate 743 trial, published in The Lancet in 2021
5-year relative survival, localized pleural mesothelioma	Survival compared with people of the same age and sex in the general population	24% for localized disease	American Cancer Society, based on SEER data for pleural mesothelioma diagnosed 2012–2018
5-year relative survival, regional pleural mesothelioma	Cancer has spread to nearby structures or lymph nodes	16% for regional disease	American Cancer Society, SEER 2012–2018
5-year relative survival, distant pleural mesothelioma	Cancer has spread to distant parts of the body	7% for distant disease	American Cancer Society, SEER 2012–2018

Median survival and 5-year relative survival answer different questions. Median survival describes the midpoint of a defined group over months.

Relative survival estimates the percentage alive after a set period, after adjusting for expected deaths in a comparable general population.

Cell type is one of the strongest predictors. In CheckMate 743, patients with non-epithelioid tumors had median overall survival of 18.1 months with nivolumab plus ipilimumab versus 8.8 months with chemotherapy.

For epithelioid tumors, the figures were 18.7 months versus 16.5 months.

Epithelioid disease generally has a better prognosis and is more likely to be considered for multimodality treatment.
Sarcomatoid and biphasic disease are usually more aggressive, although immunotherapy data have improved expectations for some patients.
Performance status, meaning how well a person can carry out daily activities, strongly affects treatment options and survival.
Stage at diagnosis matters because pleural mesothelioma is often found after it has spread within the chest.

Life-expectancy estimates should be treated as planning tools, not predictions. A mesothelioma specialist can interpret imaging, pathology, biomarkers, lung function, and treatment goals in context.

Acting on web averages alone can lead to harmful medical, legal, or financial choices.

Waiting room contains chairs, lung brochures, documents, and framed wall charts. Photographed for this guide to pleural mesothelioma survival rate.

What Coin Abul independently reviewed

Coin Abul independently reviewed public cancer-survival sources, clinical-trial reports, and federal cancer definitions to summarize pleural mesothelioma survival rates.

The figures below describe groups of patients, not a prediction for any one person.

Survival for pleural mesothelioma is usually reported as relative survival, median overall survival, or trial-specific overall survival.

These measures are not interchangeable, so Coin Abul separated population statistics from treatment-study results.

Source reviewed	Population or measure	Reported figure
American Cancer Society, using SEER 2012-2018 data	5-year relative survival for pleural mesothelioma, localized disease	24%
American Cancer Society, using SEER 2012-2018 data	5-year relative survival for pleural mesothelioma, regional disease	16%
American Cancer Society, using SEER 2012-2018 data	5-year relative survival for pleural mesothelioma, distant disease	7%
American Cancer Society, using SEER 2012-2018 data	5-year relative survival for pleural mesothelioma, all SEER stages combined	12%
CheckMate 743 trial, reported in The Lancet	Median overall survival with nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma	18.1 months
CheckMate 743 trial, reported in The Lancet	Median overall survival with platinum-plus-pemetrexed chemotherapy	14.1 months

The American Cancer Society’s SEER-based numbers were the clearest public benchmark for broad survival. “Localized” means cancer has not spread outside the pleura in SEER’s summary-stage system.

While “regional” and “distant” describe wider spread.

Clinical-trial figures were reviewed separately because trial participants may be healthier, more closely monitored, or selected by treatment eligibility.

CheckMate 743 studied unresectable malignant pleural mesothelioma and compared immunotherapy against chemotherapy, so its numbers should not be applied to every diagnosis.

Stage matters: Earlier-stage pleural mesothelioma generally has better survival than disease that has spread, as shown by the American Cancer Society’s 24%, 16%, and 7% 5-year relative-survival estimates.
Treatment eligibility matters: Surgery, chemotherapy, immunotherapy, radiation, and supportive care are not appropriate for every patient. Eligibility depends on tumor stage, cell type, lung function, performance status, and other medical conditions.
Cell type matters: The National Cancer Institute identifies epithelioid, sarcomatoid, and biphasic mesothelioma as major histologic types, and prognosis differs by type.
Dates matter: SEER survival statistics often reflect people diagnosed years earlier, so they may not fully capture newer immunotherapy use.

Caution: A patient should not use survival-rate tables alone to delay treatment, choose a therapy, settle a legal claim, or estimate compensation.

A mesothelioma specialist, and when relevant a qualified attorney or financial professional, should review the individual facts.

Questions to ask a mesothelioma specialist

Pleural mesothelioma survival varies widely by cancer stage, cell type, overall health, and whether treatment is done at a high-volume center.

A specialist should explain prognosis using your pathology report, imaging, and treatment options—not averages alone.

Bring a written question list and someone who can take notes. Caution: Do not delay diagnosis or treatment decisions based only on general survival statistics online; ask the treating physician how the data applies to the individual case.

Key questions about diagnosis and staging

What type of pleural mesothelioma is it? Ask whether pathology shows epithelioid, biphasic, or sarcomatoid disease. The American Cancer Society says epithelioid mesothelioma generally has a better outlook than sarcomatoid disease.
What stage is the cancer? Ask which staging system was used and whether the disease is resectable. The National Cancer Institute explains that stage helps guide treatment and prognosis.
Has the biopsy been reviewed by a mesothelioma pathologist? Misclassification can affect treatment choices, so confirmation at an experienced cancer center may matter.

Questions about survival statistics

Question to ask	Why it matters	Source-based fact
What survival range fits this specific case?	Averages may not reflect age, stage, cell type, or fitness for treatment.	The American Cancer Society reports a 5-year relative survival rate of about 12% for pleural mesothelioma overall, based on SEER data for cases diagnosed from 2013 to 2019.
How does stage change expected survival?	Localized disease often has better outcomes than distant disease.	American Cancer Society SEER data lists 5-year relative survival of about 24% for localized pleural mesothelioma and about 7% for distant disease.
What does “median survival” mean in this context?	Median survival is not a deadline; half of patients lived longer in the study group.	The National Cancer Institute defines median survival as the time at which half of people in a group are still alive.

Questions about treatment choices

Am I a candidate for surgery? Ask about pleurectomy/decortication and extrapleural pneumonectomy, including risks, recovery time, and whether surgery is recommended only with chemotherapy, immunotherapy, or radiation.
What systemic treatments fit my case? Ask about platinum-based chemotherapy, pemetrexed, immunotherapy, and clinical trials. The FDA approved nivolumab plus ipilimumab in 2020 for unresectable malignant pleural mesothelioma.
What are the realistic goals? Clarify whether treatment aims to extend survival, shrink tumors, control fluid buildup, reduce pain, or preserve breathing function.
Are clinical trials available? Ask the specialist to search ClinicalTrials.gov and major cancer centers, because trial eligibility depends on stage, prior treatment, biomarkers, and performance status.
How will palliative care be included? The National Cancer Institute describes palliative care as supportive care that can be provided alongside cancer treatment, not only at the end of life.

Before choosing a plan, ask for the expected benefits, major side effects, alternatives, and what happens if treatment is stopped. Caution: Legal, compensation, or insurance decisions should be reviewed with qualified professionals,.

Not based on medical survival estimates alone.

Frequently Asked Questions

What is the average survival rate for pleural mesothelioma?

The American Cancer Society, using SEER data for cases diagnosed from 2013 to 2019, reports a 5-year relative survival rate of about 12% for pleural mesothelioma overall.

This figure is a population estimate, not a prediction for any one person, so patients should review their own prognosis with a mesothelioma specialist.

How does stage affect pleural mesothelioma survival?

The American Cancer Society reports 5-year relative survival rates of about 24% for localized pleural mesothelioma, 16% for regional disease and 7% for distant disease, based on SEER data from 2013 to 2019.

Staging systems and treatment options are complex, so no one should make treatment decisions from survival statistics alone.

Does surgery improve survival for pleural mesothelioma?

For carefully selected patients, surgery may be part of multimodal treatment, but it is not appropriate for everyone.

The National Cancer Institute’s PDQ notes that treatment choices depend on factors such as disease stage, tumor location, symptoms and overall health, so eligibility should be assessed by an experienced mesothelioma care team.

Do newer treatments change pleural mesothelioma survival expectations?

Yes, some systemic therapies have improved outcomes in clinical trials.

The U.S. Food and Drug Administration approved nivolumab plus ipilimumab for unresectable malignant pleural mesothelioma in 2020 after the CheckMate 743 trial showed median overall survival of 18.1 months with the immunotherapy combination versus 14.1.

Months with chemotherapy.

Why do pleural mesothelioma survival numbers vary between sources?

Survival figures vary because sources may use different populations, diagnosis years, disease stages, treatments and measures such as median survival or 5-year relative survival.

Readers should check the original source, such as SEER, the American Cancer Society, the National Cancer Institute or a published clinical trial, before relying on any single number.

What factors besides stage can affect pleural mesothelioma survival?

Survival varies by cell type, age, overall health, performance status, and treatment, not stage alone.

The article states epithelial mesothelioma has a better prognosis than sarcomatoid or biphasic disease, but individual estimates require pathology review and staging.

Better outlook is generally linked to earlier stage, epithelial cell type, good functional status, younger age, and access to specialist care.

Worse outlook is generally linked to distant spread, sarcomatoid histology, poor performance status, weight loss, and major coexisting illness.